Patients get continued access to cancer drug after trial ends
NCT ID NCT06572982
Summary
This study allows a small group of patients with acute myeloid leukemia (AML) to continue receiving a generic oral version of the drug azacitidine after they finished a previous trial. The main goal is to monitor the safety and side effects of the drug when taken for a longer period. It is offered as a compassionate use program for patients who were already taking the drug in the earlier study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sheikh Shakhbout Medical City
Abu Dhabi, United Arab Emirates
Conditions
Explore the condition pages connected to this study.